Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes

Experimental and Molecular Pathology

Volumn 98, Issue 1, 2015, Pages 47-54

  Noske, Aurelia ^a   Henricksen, Leigh A ^b   LaFleur, Bonnie ^b   Zimmermann, Anne Katrin ^a   Tubbs, Alisa ^b   Singh, Shalini ^b   Storz, Martina ^a   Fink, Daniel ^c   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

Author keywords

19q12; CCNE1; Cyclin E1; Epithelial ovarian cancer; ISH; URI

Indexed keywords

CCNE1 PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; ONCOPROTEIN; SIGNAL PEPTIDE; URI1 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; CANCER GRADING; CANCER STAGING; CHROMOSOME 19; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 19; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84919941491     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.12.004     Document Type: Article

References (23)

1. Bedrosian I., Lu K.H., Verschraegen C., Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004, 23:2648-2657.
2. Bowtell D.D. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer 2010, 10:803-808.
3. Cancer Genome Atlas Research N Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
4. Cicenas J., Valius M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol. 2011, 137:1409-1418.
5. Davis S.J., Sheppard K.E., Pearson R.B., Campbell I.G., Gorringe K.L., Simpson K.J. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer. Clin. Cancer Res. 2013, 19:1411-1421.
6. Etemadmoghadam D., deFazio A., Beroukhim R., Mermel C., George J., Getz G., Tothill R., Okamoto A., Raeder M.B., Harnett P., Lade S., Akslen L.A., Tinker A.V., Locandro B., Alsop K., Chiew Y.E., Traficante N., Fereday S., Johnson D., Fox S., Sellers W., Urashima M., Salvesen H.B., Meyerson M., Bowtell D. Group AS: integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 2009, 15:1417-1427.
7. Etemadmoghadam D., George J., Cowin P.A., Cullinane C., Kansara M., Australian Ovarian Cancer Study G, Gorringe K.L., Smyth G.K., Bowtell D.D. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 2010, 5:e15498.
8. Etemadmoghadam D., Weir B.A., Au-Yeung G., Alsop K., Mitchell G., George J., Australian Ovarian Cancer Study G, Davis S., D'Andrea A.D., Simpson K., Hahn W.C., Bowtell D.D. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:19489-19494.
9. Etemadmoghadam D., Au-Yeung G., Wall M., Mitchell C., Kansara M., Loehrer E., Batzios C., George J., Ftouni S., Weir B.A., Carter S., Gresshoff I., Mileshkin L., Rischin D., Hahn W.C., Waring P.M., Getz G., Cullinane C., Campbell L.J., Bowtell D.D. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin. Cancer Res. 2013, 19:5960-5971.
10. Heeran M.C., Hogdall C.K., Kjaer S.K., Christensen L., Blaakaer J., Christensen I.J., Hogdall E.V. Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study. APMIS 2012, 120:846-854.
11. Karst A.M., Jones P.M., Vena N., Ligon A.H., Liu J.F., Hirsch M.S., Etemadmoghadam D., Bowtell D.D., Drapkin R. Cyclin e1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 2014, 74:1141-1152.
12. Kuhn E., Bahadirli-Talbott A., Shih Ie M. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod. Pathol. 2014, 27:1014-1019.
13. Lapenna S., Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8:547-566.
14. Leung S.Y., Ho C., Tu I.P., Li R., So S., Chu K.M., Yuen S.T., Chen X. Comprehensive analysis of 19q12 amplicon in human gastric cancers. Mod. Pathol. 2006, 19:854-863.
15. Lin L., Prescott M.S., Zhu Z., Singh P., Chun S.Y., Kuick R.D., Hanash S.M., Orringer M.B., Glover T.W., Beer D.G. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res. 2000, 60:7021-7027.
16. Mayr D., Kanitz V., Anderegg B., Luthardt B., Engel J., Lohrs U., Amann G., Diebold J. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am. J. Clin. Pathol. 2006, 126:101-109.
17. Nakayama N., Nakayama K., Shamima Y., Ishikawa M., Katagiri A., Iida K., Miyazaki K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010, 116:2621-2634.
18. Natrajan R., Mackay A., Wilkerson P.M., Lambros M.B., Wetterskog D., Arnedos M., Shiu K.K., Geyer F.C., Langerod A., Kreike B., Reyal F., Horlings H.M., van de Vijver M.J., Palacios J., Weigelt B., Reis-Filho J.S. Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res. 2012, 14:R53.
19. Pils D., Bachmayr-Heyda A., Auer K., Svoboda M., Auner V., Hager G., Obermayr E., Reiner A., Reinthaller A., Speiser P., Braicu I., Sehouli J., Lambrechts S., Vergote I., Mahner S., Berger A., Cacsire Castillo-Tong D., Zeillinger R. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. Eur. J. Cancer 2014, 50:99-110.
20. Rechsteiner M., Zimmermann A.K., Wild P.J., Caduff R., von Teichman A., Fink D., Moch H., Noske A. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp. Mol. Pathol. 2013, 95:235-241.
21. Schraml P., Bucher C., Bissig H., Nocito A., Haas P., Wilber K., Seelig S., Kononen J., Mihatsch M.J., Dirnhofer S., Sauter G. Cyclin E overexpression and amplification in human tumours. J. Pathol. 2003, 200:375-382.
22. Siu K.T., Rosner M.R., Minella A.C. An integrated view of cyclin E function and regulation. Cell Cycle 2012, 11:57-64.
23. Theurillat J.P., Metzler S.C., Henzi N., Djouder N., Helbling M., Zimmermann A.K., Jacob F., Soltermann A., Caduff R., Heinzelmann-Schwarz V., Moch H., Krek W. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 2011, 19:317-332.